Nonclinical precedent Request an invite

Bimzelx: how long were the pivotal tox studies?

bimekizumab · IL-17A/IL-17F
Longest pivotal study
26 weeks
“The Applicant has conducted repeat dose toxicity studies in cynomolgus monkeys with weekly doses administered by subcutaneous injection for up to 26 weeks, followed by a treatment-free recovery period of up to 21 weeks”
✓ VerifiedFDA multi-discipline review, p. 205Source ↗
Pivotal GLP studies
Cynomolgus monkey weekly SC repeat-dose studies up to 26 weeks with up to 21-week recovery
“The Applicant has conducted repeat dose toxicity studies in cynomolgus monkeys with weekly doses administered by subcutaneous injection for up to 26 weeks, followed by a treatment-free recovery period of up to 21 weeks”
✓ VerifiedFDA multi-discipline review, p. 205Source ↗
Route in tox
Subcutaneous and intravenous
“Intravenous and subcutaneous routes of administration were explored.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Same question, other monoclonal antibodies

Actemra

tocilizumab · IL-6R
26 weeks

Adakveo

crizanlizumab · P-selectin
26 weeks

Adbry

tralokinumab · IL-13
26 weeks

Aduhelm

aducanumab · Aggregated amyloid-β
26 weeks

Aimovig

erenumab · CGRP receptor
26 weeks

Ajovy

fremanezumab · CGRP
26 weeks

Alhemo

concizumab · TFPI
52 weeks

Andembry

garadacimab · Factor XIIa
26 weeks

Anthim

obiltoxaximab · B. anthracis PA
1 (dosing on Days 1, 4 and 7 in rats)

Arzerra

ofatumumab · CD20
30 (7 months)

Avastin

bevacizumab · VEGF-A
26 weeks

Benlysta

belimumab · BLyS (BAFF)
26 weeks

Cablivi

caplacizumab · von Willebrand factor (A1 domain)
26 weeks

Cimzia

certolizumab pegol · TNF-α
52 weeks

Cyramza

ramucirumab · VEGFR2
39 weeks

Ebanga

ansuvimab · Zaire ebolavirus glycoprotein
4 weeks

Ebglyss

lebrikizumab · IL-13
39 weeks

Empliciti

elotuzumab · SLAMF7
0 (no repeat-dose toxicity studies)

Enflonsia

clesrovimab · RSV F protein (site IV)
2 weeks

Enjaymo

sutimlimab · Complement C1s
26 weeks

Entyvio

vedolizumab · α4β7-integrin
26 weeks

Evenity

romosozumab · Sclerostin
26 weeks

Evkeeza

evinacumab · ANGPTL3
26 weeks

Fasenra

benralizumab · IL-5Rα
39 weeks

Gazyva

obinutuzumab · CD20
26 weeks

Humira

adalimumab · TNF-α
39 weeks

Ilaris

canakinumab · IL-1β
26 weeks

Ilumya

tildrakizumab · IL-23 p19
39 weeks

Imaavy

nipocalimab · FcRn
26 weeks

Imjudo

tremelimumab · CTLA-4
26 weeks

Kisunla

donanemab · Amyloid-β (N3pG)
22 weeks

Leqembi

lecanemab · Amyloid-β protofibrils
39 weeks

Nucala

mepolizumab · IL-5
26 weeks

Omvoh

mirikizumab · IL-23 p19
26 weeks

Opdivo

nivolumab · PD-1
13 weeks

Pasatru

garetosmab · Activin A
26 weeks

Piasky

crovalimab · Complement C5
26 weeks

Praxbind

idarucizumab · Dabigatran
4 weeks

Prolia

denosumab · RANKL
52 weeks

Raxibacumab

raxibacumab · B. anthracis protective antigen
3 weeks

Remicade

infliximab · TNF-α
26 (mouse surrogate antibody)

Siliq

brodalumab · IL-17RA
26 weeks

Simulect

basiliximab · IL-2Rα (CD25)
4 weeks

Skyrizi

risankizumab · IL-23 p19
26 weeks

Soliris

eculizumab · Complement C5
26 weeks

Spevigo

spesolimab · IL-36R
26 weeks

Stelara

ustekinumab · IL-12/23 p40
26 weeks

Synagis

palivizumab · RSV F protein
0 (no repeat-dose studies; single-dose only)

Takhzyro

lanadelumab · Plasma kallikrein
26 weeks

Taltz

ixekizumab · IL-17A
39 weeks

Tepezza

teprotumumab · IGF-1R
39 weeks

Tremfya

guselkumab · IL-23 p19
24 weeks

Tysabri

natalizumab · α4-integrin
26 weeks

Tzield

teplizumab · CD3
1 weeks

Ultomiris

ravulizumab · Complement C5
26 weeks

Uplizna

inebilizumab · CD19
26 weeks

Veopoz

pozelimab · Complement C5
26 weeks

Voyxact

sibeprenlimab · APRIL
26 weeks

Vyepti

eptinezumab · CGRP
26 weeks

Vyloy

zolbetuximab · Claudin 18.2
13 weeks

Xolair

omalizumab · IgE
26 weeks

Yervoy

ipilimumab · CTLA-4
26 weeks

Zinbryta

daclizumab · IL-2Rα (CD25)
39 weeks

Zinplava

bezlotoxumab · C. difficile toxin B
3 weeks

Zynyz

retifanlimab · PD-1
13 weeks

Beovu

brolucizumab · VEGF-A
Not stated in public reviews

Summary across all 117 monoclonal antibodies →